Biological Modification of Arrhythmogenic Substrates by Cell-Free Therapeutics
- PMID: 37353457
- PMCID: PMC10526725
- DOI: 10.1016/j.hlc.2023.05.016
Biological Modification of Arrhythmogenic Substrates by Cell-Free Therapeutics
Abstract
Ventricular arrhythmias (VAs) represent a major cause of sudden cardiac death and afflict patients with heart failure from both ischaemic and non-ischaemic origins, and inherited cardiomyopathies. Current VA management, including anti-arrhythmic medications, autonomic modulation, implantable cardioverter-defibrillator implantation, and catheter ablation, remains suboptimal. Catheter ablation may even cause significant cardiomyocyte loss. Cell-based therapies and exosome treatment have been proposed as promising strategies to lessen cardiomyocyte death, modulate immune reaction, and reduce myocardial scarring, and, therefore, are potentially beneficial in treating VAs. In this review, we summarise the current cornerstones of VA management. We also discuss recent advances and ongoing evidence regarding cell-based and exosome therapy, with special attention to VA treatment.
Keywords: Cardiosphere-derived cells; Catheter ablation; Exosomes; Extracellular Vesicles; Stem cells; Ventricular arrhythmias.
Copyright © 2023 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.
Figures



Similar articles
-
Interventional electrophysiology and its role in the treatment of cardiac arrhythmia.Ann Acad Med Singap. 1998 Mar;27(2):248-54. Ann Acad Med Singap. 1998. PMID: 9663319 Review.
-
Management of Ventricular Arrhythmias in Heart Failure.Curr Heart Fail Rep. 2023 Aug;20(4):237-253. doi: 10.1007/s11897-023-00608-y. Epub 2023 May 25. Curr Heart Fail Rep. 2023. PMID: 37227669 Review.
-
Sudden death related cardiomyopathies - Arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, and exercise-induced cardiomyopathy.Prog Cardiovasc Dis. 2019 May-Jun;62(3):217-226. doi: 10.1016/j.pcad.2019.04.002. Epub 2019 Apr 17. Prog Cardiovasc Dis. 2019. PMID: 31004608 Review.
-
Catheter Ablation of VT in Non-Ischaemic Cardiomyopathies: Endocardial, Epicardial and Intramural Approaches.Heart Lung Circ. 2019 Jan;28(1):84-101. doi: 10.1016/j.hlc.2018.10.007. Epub 2018 Oct 19. Heart Lung Circ. 2019. PMID: 30385114 Review.
-
Ventricular Arrhythmias in Cardiac Sarcoidosis.Circulation. 2018 Sep 18;138(12):1253-1264. doi: 10.1161/CIRCULATIONAHA.118.034687. Circulation. 2018. PMID: 30354431 Review.
Cited by
-
Intracoronary-Cardiosphere-Derived Cell Secretome Therapy: Effects on Ventricular Tachycardia Inducibility and Cardiac Function in a Swine Model.Biomedicines. 2025 Apr 25;13(5):1043. doi: 10.3390/biomedicines13051043. Biomedicines. 2025. PMID: 40426870 Free PMC article.
-
Gene- and cell-based therapy in cardiovascular diseases.J Cardiovasc Pharmacol. 2025 Apr 30;86(2):157-65. doi: 10.1097/FJC.0000000000001707. Online ahead of print. J Cardiovasc Pharmacol. 2025. PMID: 40305441 Free PMC article.
References
-
- Gräni C, Benz DC, Gupta S, Windecker S, Kwong RY. Sudden cardiac death in ischemic heart disease: from imaging arrhythmogenic substrate to guiding therapies. JACC: Cardiovasc Imaging. 2020;13:2223–38. - PubMed
-
- Kirubakaran S, Bisceglia C, Silberbauer J, Oloriz T, Santagostino G, Yamase M, et al. Characterization of the arrhythmogenic substrate in patients with arrhythmogenic right ventricular cardiomyopathy undergoing ventricular tachycardia ablation. EP Europace. 2017;19:1049–62. - PubMed
-
- Pappone C, Ciconte G, Manguso F, Vicedomini G, Mecarocci V, Conti M, et al. Assessing the malignant ventricular arrhythmic substrate in patients with Brugada syndrome. J Am Coll Cardiol. 2018;71:1631–46. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical